
## **Stephane Picot**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5141229/publications.pdf Version: 2024-02-01



STEDHANE DICOT

#	Article	IF	CITATIONS
1	Synthesis of Fatty 1,2,4-Trioxanes by Peracetalization of β-Hydroxy Hydroperoxides. Synthesis, 2022, 54, 617-628.	2.3	2
2	Drug resistant parasites and fungi from a one-health perspective: A global concern that needs transdisciplinary stewardship programs. One Health, 2022, 14, 100368.	3.4	10
3	Assessment of quantitative and semi-quantitative biological test methods of artesunate <i>in vitro</i> . Parasite, 2022, 29, 18.	2.0	1
4	Diagnostic accuracy of fluorescence flow-cytometry technology using Sysmex XN-31 for imported malaria in a non-endemic setting. Parasite, 2022, 29, 31.	2.0	3
5	Recrudescence of a high parasitaemia, severe Plasmodium falciparum malaria episode, treated by artesunate monotherapy. International Journal of Infectious Diseases, 2021, 105, 345-348.	3.3	6
6	Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa, 2013–18. Journal of Antimicrobial Chemotherapy, 2020, 75, 2141-2148.	3.0	5
7	Systematic review of registered trials of Hydroxychloroquine prophylaxis for COVID-19 health-care workers at the first third of 2020. One Health, 2020, 10, 100141.	3.4	15
8	The End of the Artemisinin Era—We Should Aim at Malaria Eradication in Asia Using Free, Effective Treatment. Clinical Infectious Diseases, 2020, 73, 414-415.	5.8	0
9	Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates. Malaria Journal, 2020, 19, 201.	2.3	11
10	Mycetoma and Chromoblastomycosis: Perspective for Diagnosis Improvement Using Biomarkers. Molecules, 2020, 25, 2594.	3.8	11
11	Systematic review and meta-analysis of diagnostic accuracy of loop-mediated isothermal amplification (LAMP) methods compared with microscopy, polymerase chain reaction and rapid diagnostic tests for malaria diagnosis. International Journal of Infectious Diseases, 2020, 98, 408-419.	3.3	32
12	Dual shape recovery of red blood cells flowing out of a microfluidic constriction. Biomicrofluidics, 2020, 14, 024116.	2.4	13
13	Cryptosporidiosis in HIV-positive patients and related risk factors: A systematic review and meta-analysis. Parasite, 2020, 27, 27.	2.0	33
14	Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health, 2020, 9, 100131.	3.4	21
15	Flagging performance of Sysmex XN-10 haematology analyser for malaria detection. Journal of Clinical Pathology, 2020, 73, 676-677.	2.0	6
16	Plasmodium. , 2020, , .		2
17	Genetic polymorphisms with erythrocyte traits in malaria endemic areas of Mali. PLoS ONE, 2019, 14, e0209966.	2.5	1
18	Systematic review of artesunate pharmacokinetics: Implication for treatment of resistant malaria. International Journal of Infectious Diseases, 2019, 89, 30-44.	3.3	16

#	Article	IF	CITATIONS
19	Comparison of <i>fks</i> gene mutations and minimum inhibitory concentrations for the detection of <i>Candida glabrata</i> resistance to micafungin: A systematic review and metaâ€analysis. Mycoses, 2019, 62, 835-846.	4.0	8
20	Antimalarial stewardship programs are urgently needed for malaria elimination: a perspective. Parasite, 2019, 26, 16.	2.0	8
21	Interactions between hydatid cyst and regulated cell death may provide new therapeutic opportunities. Parasite, 2019, 26, 70.	2.0	10
22	Automated <i>Plasmodium</i> detection by the Sysmex XN hematology analyzer. Journal of Clinical Pathology, 2018, 71, 594-599.	2.0	13
23	Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet, The, 2018, 391, 1378-1390.	13.7	93
24	Guidelines and recommendations on yeast cell death nomenclature. Microbial Cell, 2018, 5, 4-31.	3.2	158
25	Sleep patterns in villagers and urban African volunteers in a humid tropical climate: Influence of accessibility to electric light?. Journal of the Neurological Sciences, 2017, 376, 44-48.	0.6	4
26	An outbreak of locally acquired Plasmodium vivax malaria among migrant workers in Oman. Parasite, 2017, 24, 25.	2.0	11
27	Genetic diversity of Plasmodium vivax metacaspase 1 and Plasmodium vivax multi-drug resistance 1 genes of field isolates from Mauritania, Sudan and Oman. Malaria Journal, 2017, 16, 61.	2.3	5
28	Cryptic Plasmodium ovale concurrent with mixed Plasmodium falciparum and Plasmodium malariae infection in two children from Central African Republic. Malaria Journal, 2017, 16, 339.	2.3	13
29	Diagnostic accuracy of loop-mediated isothermal amplification (LAMP) for screening patients with imported malaria in a non-endemic setting. Parasite, 2017, 24, 53.	2.0	30
30	malERA: An updated research agenda for insecticide and drug resistance in malaria elimination and eradication. PLoS Medicine, 2017, 14, e1002450.	8.4	55
31	Interaction between environment, nutrient-derived metabolites and immunity: A possible role in malaria susceptibility/resistance in Fulani and Dogon of Mali. PLoS ONE, 2017, 12, e0189724.	2.5	4
32	Do advanced glycation end-products play a role in malaria susceptibility?. Parasite, 2016, 23, 15.	2.0	16
33	Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. International Journal of Infectious Diseases, 2016, 46, 11-17.	3.3	85
34	A matched case–control study of toxoplasmosis after allogeneic haematopoieticÂstem cell transplantation: still a devastating complication. Clinical Microbiology and Infection, 2016, 22, 636-641.	6.0	35
35	7-Chloro-4-aminoquinoline γ-hydroxy-γ-lactam derived-tetramates as a new family of antimalarial compounds. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5308-5311.	2.2	5
36	Actinomycosis after allogeneic hematopoietic stem cell transplantation despite penicillin prophylaxis. Transplant Infectious Disease, 2016, 18, 595-600.	1.7	6

#	Article	IF	CITATIONS
37	HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns. Journal of Infection, 2016, 72, 214-222.	3.3	32
38	Improvement in the Outcome of Invasive Aspergillosis in a Pediatric Hematology Department. Journal of Pediatric Hematology/Oncology, 2015, 37, 560-565.	0.6	12
39	Refined Method for Droplet Microfluidics-Enabled Detection of Plasmodium falciparum Encoded Topoisomerase I in Blood from Malaria Patients. Micromachines, 2015, 6, 1505-1513.	2.9	8
40	The Other Face of Artesunate: Southern Drug to Treat Northern Diseases. EBioMedicine, 2015, 2, 17-18.	6.1	2
41	Dermatophytes and Transmission Risks to Family: A Retrospective Study of a Cohort of 256 Adopted Children from 1998 to 2012. Pediatric Dermatology, 2015, 32, 426-427.	0.9	4
42	Drying anti-malarial drugs in vitro tests to outsource SYBR green assays. Malaria Journal, 2015, 14, 90.	2.3	5
43	Wanted Plasmodium falciparum, dead or alive. Microbial Cell, 2015, 2, 219-224.	3.2	6
44	Erythropoietin Combined with Liposomal Amphotericin B Improves Outcome during Disseminated Aspergillosis in Mice. Frontiers in Immunology, 2014, 5, 502.	4.8	5
45	Efficacy of intranasal administration of artesunate in experimental cerebral malaria. Malaria Journal, 2014, 13, 501.	2.3	20
46	Impact of Scedosporium apiospermum complex seroprevalence in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 667-673.	0.7	27
47	Genetic diversity and population structure of Plasmodium vivax isolates from Sudan, Madagascar, French Guiana and Armenia. Infection, Genetics and Evolution, 2014, 27, 244-249.	2.3	9
48	Ophthalmic Outcomes of Congenital Toxoplasmosis Followed Until Adolescence. Pediatrics, 2014, 133, e601-e608.	2.1	69
49	Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12. Journal of Antimicrobial Chemotherapy, 2014, 69, 2706-2712.	3.0	51
50	New Anti-Malarial Drugs: Who Cares?. Current Topics in Medicinal Chemistry, 2014, 14, 1637-1642.	2.1	4
51	Evaluation of the malaria rapid diagnostic test VIKIA malaria Ag Pf/Panâ"¢ in endemic and non-endemic settings. Malaria Journal, 2013, 12, 188.	2.3	23
52	Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000–2011. Malaria Journal, 2013, 12, 35.	2.3	28
53	Incorporation of a 3-(2,2,2-Trifluoroethyl)-γ-hydroxy-γ-lactam Motif in the Side Chain of 4-Aminoquinolines. Syntheses and Antimalarial Activities. Journal of Medicinal Chemistry, 2013, 56, 73-83.	6.4	70
	New route to the 5-((arylthio- and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 72 Td (heteroarylthio)methylene)-3-(2	2,2,2-trifluo	roethyl)-furan
54	of 4-aminoquinoline Î <sup>3</sup> -lactams as potent antimalarial compounds. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 6167-6171.	2.2	25

#	Article	IF	CITATIONS
55	Cerebral Malaria: Protection by Erythropoietin. Methods in Molecular Biology, 2013, 982, 315-324.	0.9	6
56	Plasmodium vivax malaria: A re-emerging threat for temperate climate zones?. Travel Medicine and Infectious Disease, 2013, 11, 51-59.	3.0	26
57	A Multicenter, Randomized, Open-Label, Controlled Study Comparing the Efficacy, Safety and Cost-Effectiveness of a Sequential Therapy with RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-Forming Solution with Amorolfine Nail Lacquer Alone in Dermatophytic Onychomycosis, Dermatology, 2013, 227, 157-164.	2.1	16
58	<i>Candida albicans</i> and non- <i>Candida albicans</i> fungemia in an institutional hospital during a decade. Medical Mycology, 2013, 51, 33-37.	0.7	44
59	Estimation of the incubation period of invasive aspergillosis by survival models in acute myeloid leukemia patients. Medical Mycology, 2013, 51, 214-218.	0.7	12
60	RELATIONSHIP BETWEEN BASELINE CLINICAL DATA AND MICROBIOLOGIC SPECTRUM IN 100 PATIENTS WITH ACUTE POSTCATARACT ENDOPHTHALMITIS. Retina, 2012, 32, 549-557.	1.7	40
61	Cutaneous cryptococcosis in solid organ transplant recipients: epidemiological, clinical, diagnostic and therapeutic features. European Journal of Dermatology, 2012, 22, 651-657.	0.6	13
62	Droplet Microfluidics Platform for Highly Sensitive and Quantitative Detection of Malaria-Causing <i>Plasmodium</i> Parasites Based on Enzyme Activity Measurement. ACS Nano, 2012, 6, 10676-10683.	14.6	81
63	Therapeutic efficacy of artemether-lumefantrine for Plasmodium vivax infections in a prospective study in Guyana. Malaria Journal, 2012, 11, 347.	2.3	10
64	Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 991-997.	2.9	41
65	Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum. Malaria Journal, 2012, 11, 45.	2.3	26
66	Good efficacy of artemether-lumefantrine for uncomplicated falciparum malaria in eastern Sumba, East Nusatenggara, Indonesia. Acta Medica Indonesiana, 2012, 44, 187-92.	0.9	2
67	Maxillary sinus fungal infection by Acremonium. European Annals of Otorhinolaryngology, Head and Neck Diseases, 2011, 128, 41-43.	0.7	12
68	Are protozoan metacaspases potential parasite killers?. Parasites and Vectors, 2011, 4, 26.	2.5	40
69	Teigne du cuir chevelu paucisymptomatique et transmission intrafamilialeÂ: conduite à tenir. Journal De Mycologie Medicale, 2011, 21, 298-300.	1.5	1
70	Plasmodium falciparum Metacaspase PfMCA-1 Triggers a z-VAD-fmk Inhibitable Protease to Promote Cell Death. PLoS ONE, 2011, 6, e23867.	2.5	37
71	Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica, 2011, 96, 1685-1691.	3.5	63
72	Update on genetic markers of quinine resistance in Plasmodium falciparum. Molecular and Biochemical Parasitology, 2011, 177, 77-82.	1.1	26

#	Article	IF	CITATIONS
73	Étude des onychomycoses en médecine de ville dans la région lyonnaise. Journal De Mycologie Medicale, 2011, 21, 118-122.	1.5	13
74	ClickEnam. 1. Synthesis of novel 1,4-disubsituted-[1,2,3]-triazole-derived β-aminovinyl trifluoromethylated ketones and their copper(II) complexes. Journal of Fluorine Chemistry, 2011, 132, 850-857.	1.7	17
75	Advantages and limits of real-time PCR assay and PCR-restriction fragment length polymorphism for the identification of cutaneous Leishmania species in Tunisia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011, 105, 17-22.	1.8	34
76	Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Medical Mycology, 2011, 49, 1-7.	0.7	36
77	Low infectivity of Plasmodium falciparum gametocytes to Anopheles gambiae following treatment with sulfadoxine–pyrimethamine in Mali. International Journal for Parasitology, 2010, 40, 1213-1220.	3.1	34
78	Severe Imported Falciparum Malaria: A Cohort Study in 400 Critically Ill Adults. PLoS ONE, 2010, 5, e13236.	2.5	134
79	Apoptosis induced by parasitic diseases. Parasites and Vectors, 2010, 3, 106.	2.5	45
80	Acute Liver Failure May Lead to Lethal Pulmonary Aspergillosis. Journal of Clinical Gastroenterology, 2010, 44, 593-594.	2.2	3
81	Can erythropoietin be used to prevent brain damage in cerebral malaria?. Trends in Parasitology, 2009, 25, 30-36.	3.3	46
82	Analysis of Diluted Vitreous Samples from Vitrectomy Is Useful in Eyes with Severe Acute Postoperative Endophthalmitis. Ophthalmology, 2009, 116, 2437-2441.e1.	5.2	33
83	Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. Malaria Journal, 2009, 8, 169.	2.3	37
84	A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria Journal, 2009, 8, 89.	2.3	204
85	High Prevalence and Fixation of Plasmodium vivax dhfr/dhps Mutations Related to Sulfadoxine/Pyrimethamine Resistance in French Guiana. American Journal of Tropical Medicine and Hygiene, 2009, 81, 19-22.	1.4	16
86	High prevalence and fixation of Plasmodium vivax dhfr/dhps mutations related to sulfadoxine/pyrimethamine resistance in French Guiana. American Journal of Tropical Medicine and Hygiene, 2009, 81, 19-22.	1.4	11
87	Cutaneous leishmaniasis caused by Leishmania tropica in Algeria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 1157-1159.	1.8	17
88	Ring-infected erythrocyte surface antigen (Pf/155RESA) induces tumour necrosis factor-alpha production. Clinical and Experimental Immunology, 2008, 93, 184-188.	2.6	10
89	Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. Malaria Journal, 2008, 7, 35.	2.3	40
90	Management and prevention of imported Plasmodium falciparum malaria: Recommendations for clinical practice 2007 (Revision 2007 of the 1999 consensus conference). Short text Médecine Et Maladies Infectieuses, 2008, 38, 54-67.	5.0	21

#	Article	IF	CITATIONS
91	Artesunate–erythropoietin combination for murine cerebral malaria treatment. Acta Tropica, 2008, 106, 104-108.	2.0	38
92	<i>Plasmodium vivax</i> Resistance to Chloroquine in Madagascar: Clinical Efficacy and Polymorphisms in <i>pvmdr1</i> and <i>pvcrt-o</i> Genes. Antimicrobial Agents and Chemotherapy, 2008, 52, 4233-4240.	3.2	98
93	Contribution of the (1→3)-β- d -Glucan Assay for Diagnosis of Invasive Fungal Infections. Journal of Clinical Microbiology, 2008, 46, 1009-1013.	3.9	158
94	Molecular Markers of In Vivo <i>Plasmodium vivax</i> Resistance to Amodiaquine Plus Sulfadoxineâ€Pyrimethamine: Mutations in <i>pvdhfr</i> and <i>pvmdr1</i> . Journal of Infectious Diseases, 2008, 198, 409-417.	4.0	71
95	Statins Alone Are Ineffective in Cerebral Malaria but Potentiate Artesunate. Antimicrobial Agents and Chemotherapy, 2008, 52, 4203-4204.	3.2	22
96	Microbiologic Identification of Bleb-related Delayed-onset Endophthalmitis Caused by Moraxella Species. Journal of Glaucoma, 2008, 17, 541-545.	1.6	21
97	Eubacterial PCR for Bacterial Detection and Identification in 100 Acute Postcataract Surgery Endophthalmitis. , 2008, 49, 1971.		115
98	An Indigenous Case of Plasmodium ovale Infection in Sri Lanka. American Journal of Tropical Medicine and Hygiene, 2008, 78, 206-207.	1.4	9
99	An indigenous case of Plasmodium ovale infection in Sri Lanka. American Journal of Tropical Medicine and Hygiene, 2008, 78, 206-7.	1.4	5
100	Reply to Lackner et al Journal of Infectious Diseases, 2007, 195, 1391-1392.	4.0	0
101	Features of Apoptosis inPlasmodium falciparumErythrocytic Stage through a Putative Role of PfMCA1 Metacaspaseâ€Like Protein. Journal of Infectious Diseases, 2007, 195, 1852-1859.	4.0	103
102	Reduction of Invasive Aspergillosis Incidence among Immunocompromised Patients after Control of Environmental Exposure. Clinical Infectious Diseases, 2007, 45, 682-686.	5.8	75
103	Comparison of a SYBR Green I-Based Assay with a Histidine-Rich Protein II Enzyme-Linked Immunosorbent Assay for In Vitro Antimalarial Drug Efficacy Testing and Application to Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2007, 51, 1172-1178.	3.2	106
104	Real-time PCR assay for the identification of cutaneous Leishmania parasite species in Constantine region of Algeria. Acta Tropica, 2007, 102, 79-83.	2.0	28
105	Multicenter proficiency study for detection of Toxoplasma gondii in amniotic fluid by nucleic acid amplification methods. Clinica Chimica Acta, 2007, 375, 99-103.	1.1	36
106	Toxoplasma gondii: Comparison of human CD34+ and monocyte-derived dendritic cells after parasite infection. Experimental Parasitology, 2007, 115, 103-106.	1.2	2
107	Prevalence and Chloroquine Sensitivity of Plasmodium malariae in Madagascar. American Journal of Tropical Medicine and Hygiene, 2007, 77, 1039-1042.	1.4	13
108	Short report: prevalence and chloroquine sensitivity of Plasmodium malariae in Madagascar. American Journal of Tropical Medicine and Hygiene, 2007, 77, 1039-42.	1.4	9

#	Article	IF	CITATIONS
109	In vitro antimalarial activity of flavonoid derivatives dehydrosilybin and 8-(1;1)-DMA-kaempferide. Acta Tropica, 2006, 97, 102-107.	2.0	49
110	Melioidosis: An Imported Case From Madagascar. Journal of Travel Medicine, 2006, 13, 318-320.	3.0	30
111	Black piedra: report of a French case associated with Trichosporon asahii. International Journal of Dermatology, 2006, 45, 1258-1260.	1.0	5
112	Serotyping of Toxoplasma gondii in chronically infected pregnant women: predominance of type II in Europe and types I and III in Colombia (South America). Microbes and Infection, 2006, 8, 2333-2340.	1.9	107
113	Recombinant Human Erythropoietin Prevents the Death of Mice during Cerebral Malaria. Journal of Infectious Diseases, 2006, 193, 987-995.	4.0	94
114	Absence of nucleotide polymorphism in a Plasmodium vivax multidrug resistance gene after failure of mefloquine prophylaxis in French Guyana. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 234-237.	1.8	11
115	Toxoplasma gondii regulates recruitment and migration of human dendritic cells via different soluble secreted factors. Clinical and Experimental Immunology, 2005, 141, 475-484.	2.6	15
116	Evaluation of a Real-time PCR-based assay using the lightcycler system for detection of Toxoplasma gondii bradyzoite genes in blood specimens from patients with toxoplasmic retinochoroiditis. International Journal for Parasitology, 2005, 35, 275-283.	3.1	74
117	Disseminated cryptococcosis and histoplasmosis co-infection in a HIV-infected woman in France. Journal of Infection, 2005, 51, e173-e176.	3.3	12
118	Successful treatment of Candida glabrata peritonitis with fluconazole plus flucytosine in a premature infant following in vitro fertilization. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 704-705.	2.9	16
119	Candida species distribution in bloodstream cultures in Lyon, France, 1998–2001. European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24, 329-333.	2.9	33
120	Identification of thePlasmodium vivax mdr‣ike Gene(pvmdr1)and Analysis of Singleâ€Nucleotide Polymorphisms among Isolates from Different Areas of Endemicity. Journal of Infectious Diseases, 2005, 191, 272-277.	4.0	101
121	Real-Time PCR for Dihydrofolate Reductase Gene Single-Nucleotide Polymorphisms in Plasmodium vivax Isolates. Antimicrobial Agents and Chemotherapy, 2004, 48, 2581-2587.	3.2	40
122	Limited Value of Assays Using Detection of Immunoglobulin G Antibodies to the Two Recombinant Dense Granule Antigens, GRA1 and GRA6 Nt of Toxoplasma gondii, for Distinguishing between Acute and Chronic Infections in Pregnant Women. Vaccine Journal, 2004, 11, 1016-1021.	2.6	39
123	Two cases of subcutaneous phaeohyphomycosis due to Exophiala jeanselmei, in cardiac transplant and renal transplant patients. British Journal of Dermatology, 2004, 150, 597-598.	1.5	24
124	Heterogeneity in cellular and humoral immune responses against Toxoplasma gondii antigen in humans. Clinical and Experimental Immunology, 2004, 136, 535-541.	2.6	18
125	Fitness of Toxoplasma gondii is not related to DHFR single-nucleotide polymorphism during congenital toxoplasmosis. International Journal for Parasitology, 2004, 34, 1169-1175.	3.1	9
126	Usefulness of quantitative polymerase chain reaction in amniotic fluid as early prognostic marker of fetal infection with Toxoplasma gondii. American Journal of Obstetrics and Gynecology, 2004, 190, 797-802.	1.3	129

#	Article	lF	CITATIONS
127	Severe peritonitis due to Balantidium coli acquired in France. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 393-395.	2.9	58
128	Comparative diagnostic performance of two commercial rapid tests for malaria in a non-endemic area. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 784-786.	2.9	54
129	Alveolar echinococcosis in a patient without hepatic disturbance and with unusual humoral immune response. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 859-860.	2.9	1
130	Migration and maturation of human dendritic cells infected with depend on parasite strain type. FEMS Immunology and Medical Microbiology, 2004, 42, 321-331.	2.7	26
131	Characterization of an excreted/secreted antigen form of 14-3-3 protein in Toxoplasma gondii tachyzoites. FEMS Microbiology Letters, 2004, 234, 19-25.	1.8	18
132	Simultaneous identification of the four human Plasmodium species and quantification of Plasmodium DNA load in human blood by real-time polymerase chain reaction. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 387-390.	1.8	68
133	Subcellular localization of 14-3-3 proteins inToxoplasma gondiitachyzoites and evidence for a lipid raft-associated form. FEMS Microbiology Letters, 2003, 224, 161-168.	1.8	35
134	Binding of live conidia of Aspergillus fumigatus activates in vitro -generated human Langerhans cells via a lectin of galactomannan specificity. Clinical and Experimental Immunology, 2003, 133, 370-377.	2.6	33
135	Real-time PCR for chloroquine sensitivity assay and for pfmdr1–pfcrt single nucleotide polymorphisms in Plasmodium falciparum. Journal of Microbiological Methods, 2003, 54, 391-401.	1.6	34
136	Synergistic and antagonistic interactions between haemozoin and bacterial endotoxin on human and mouse macrophages. Parassitologia, 2003, 45, 135-40.	0.5	13
137	Cellular Immune Responses to Recombinant Antigens in Pregnant Women Chronically Infected with Toxoplasma gondii. Vaccine Journal, 2002, 9, 704-707.	3.1	27
138	Introducing antisense oligonucleotides into Pneumocystis carinii. Journal of Microbiological Methods, 2002, 50, 211-213.	1.6	6
139	Evaluation of different commercial ELISA methods for the serodiagnosis of systemic candidosis. Mycoses, 2002, 45, 455-460.	4.0	26
140	Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus. Canadian Journal of Microbiology, 2001, 47, 706-710.	1.7	8
141	Real time quantitative PCR and RT–PCR for analysis of Pneumocystis carinii hominis. Journal of Microbiological Methods, 2001, 45, 113-118.	1.6	25
142	Acquired itraconazole resistance in Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy, 2001, 47, 333-340.	3.0	135
143	Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of <i>Aspergillus fumigatus</i> . Canadian Journal of Microbiology, 2001, 47, 706-710.	1.7	1
144	Sterol composition of itraconazole-resistant and itraconazole-susceptible isolates of Aspergillus fumigatus. Canadian Journal of Microbiology, 2001, 47, 706-10.	1.7	5

#	Article	IF	CITATIONS
145	Abnormalities in liver enzymes during simultaneous therapy with itraconazole and amphotericin B in leukaemic patients. Journal of Antimicrobial Chemotherapy, 2000, 45, 928-929.	3.0	13
146	Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. Journal of Medical Microbiology, 2000, 49, 601-606.	1.8	57
147	Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii American Journal of Tropical Medicine and Hygiene, 2000, 62, 73-76.	1.4	39
148	Early Microascus cinereus Endocarditis of a Prosthetic Valve Implanted after Staphylococcus aureus Endocarditis of the Native Valve. Clinical Infectious Diseases, 1999, 29, 691-692.	5.8	19
149	Amphotericin B susceptibility testing of Candida lusitaniae isolates by flow cytofluorometry: comparison with the Etest and the NCCLS broth macrodilution method. Journal of Antimicrobial Chemotherapy, 1999, 43, 227-232.	3.0	19
150	In-vitro susceptibility of Aspergillus spp. isolates to amphotericin B and itraconazole. Journal of Antimicrobial Chemotherapy, 1999, 44, 553-555.	3.0	74
151	Evidence for cdc2 gene in Pneumocystis carinii hominis and its implication for culture. Aids, 1999, 13, 419.	2.2	8
152	INTESTINAL MICROSPORIDIOSIS OCCURRING IN TWO RENAL TRANSPLANT RECIPIENTS TREATED WITH MYCOPHENOLATE MOFETIL. Transplantation, 1999, 68, 699-701.	1.0	78
153	Detection of <i>Pneumocystis carinii</i> DNA in Blood Specimens from Human Immunodeficiency Virus-Infected Patients by Nested PCR. Journal of Clinical Microbiology, 1999, 37, 127-131.	3.9	27
154	Use of spectrophotometric reading for in vitro antifungal susceptibility testing of <i>Aspergillus</i> spp Canadian Journal of Microbiology, 1999, 45, 871-874.	1.7	1
155	Use of ivermectin for the management of scabies in a nursing home. European Journal of Dermatology, 1999, 9, 443-5.	0.6	20
156	Culture of Pneumocystis carinii sp.f. hominis. Journal of Eukaryotic Microbiology, 1999, 46, 122S.	1.7	3
157	Cdc2 gene of Pneumocystis carinii hominis and its expression during culture. Journal of Eukaryotic Microbiology, 1999, 46, 130S.	1.7	5
158	Use of spectrophotometric reading for in vitro antifungal susceptibility testing of Aspergillus spp. Canadian Journal of Microbiology, 1999, 45, 871-4.	1.7	10
159	Scbistosoma mansoni myelitis in two patients who had traveled to West Africa. Clinical Microbiology and Infection, 1998, 4, 157-159.	6.0	2
160	Human platelet inhibition ofToxoplasma gondiigrowth. Clinical and Experimental Immunology, 1998, 111, 325-333.	2.6	11
161	Fluorogenic detection of viableToxoplasma gondii. Parasite, 1998, 5, 371-373.	2.0	9
162	Detection of RAPD Markers Correlated with Chloroquine Resistance inPlasmodium falciparum. Genome Research, 1997, 7, 747-753.	5.5	4

#	Article	IF	CITATIONS
163	Chloroquine self-treatment and clinical outcome of cerebral malaria in children. Clinical and Experimental Immunology, 1997, 108, 279-283.	2.6	4
164	Apoptosis related to chloroquine sensitivity of the human malaria parasite Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 590-591.	1.8	94
165	Plasmodium falciparum persists in the placenta after three days' treatment with quinine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 431.	1.8	12
166	Specific antibody detection in human aspergillosis: a GEMO multicentre evaluation of a rapid immunoelectrophoresis method (Paragon®). Mycoses, 1996, 39, 427-432.	4.0	3
167	Intra-Erythrocytic Plasmodium falciparum Induces Up-Regulation of Inter-Cellular Adhesion Molecule-1 on Human Endothelial Cells In Vitro. Scandinavian Journal of Immunology, 1994, 39, 229-232.	2.7	17
168	The Multifactorial and Multistage Character of Protective Immunity to Plasmodium falciparum, Naturally Acquired by an Indigenous Population in Burkina Faso. Scandinavian Journal of Immunology, 1994, 39, 409-417.	2.7	8
169	Signal transduction pathways involved in tumour necrosis factor secretion by Plasmodium falciparum-stimulated human monocytes. Immunology, 1994, 83, 70-4.	4.4	7
170	Neopterin Levels in Plasma during a Longitudinal Study in an Area Endemic for Malaria. Clinical Immunology and Immunopathology, 1993, 67, 273-276.	2.0	5
171	Soluble Interleukin-2 Receptor Is Involved during Systemic Mycosis. Journal of Infectious Diseases, 1993, 168, 800-801.	4.0	1
172	Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso. Journal of Clinical Microbiology, 1993, 31, 636-641.	3.9	39
173	Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology, 1993, 80, 127-33.	4.4	53
174	Relationships between circulating S-antigens, naturally acquired antibodies to Plasmodium falciparum exoantigens and malaria attack in a mesoendemic area. Acta Tropica, 1992, 50, 295-304.	2.0	4
175	A new report of triclabendazole efficacy during invading phase fasciolasis. European Journal of Clinical Microbiology and Infectious Diseases, 1992, 11, 269-270.	2.9	13
176	Relationships between clinical protection and antibodies to Plasmodium falciparum RESA (Ring-infected Erythrocyte Surface Antigen) peptides. International Journal for Parasitology, 1991, 21, 271-274.	3.1	9
177	Chloroquine Inhibits Tumor Necrosis Factor Production by Human Macrophages In Vitro. Journal of Infectious Diseases, 1991, 164, 830-830.	4.0	53
178	Development of natural immunity in Plasmodium falciparum malaria: study of antibody response by Western immunoblotting. Journal of Clinical Microbiology, 1991, 29, 510-518.	3.9	13
179	Plasma levels of tumor necrosis factor (TNF) and neopterin during an attack of malaria. Annales De La Société Belge De Médecine Tropicale, 1991, 71, 63-6.	0.1	0
180	Correlation between β2-microglobulin and soluble interleukin-2 receptor levels in plasma of individuals living in a malarial endemic region. International Journal for Parasitology, 1990, 20, 815-817.	3.1	3

#	Article	IF	CITATIONS
181	Plasma levels of tumor necrosis factor during a longitudinal survey in an endemic area of malaria. Acta Tropica, 1990, 47, 47-51.	2.0	24
182	Tumor necrosis factor production by human macrophages stimulated in vitro by Plasmodium falciparum. Infection and Immunity, 1990, 58, 214-216.	2.2	39
183	Longitudinal survey in an endemic region of plasma soluble interleukin-2 receptor and antibody levels in Plasmodium falciparum malaria. Journal of Clinical Microbiology, 1990, 28, 1545-1550.	3.9	5